[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].
Article Details
- CitationCopy to clipboard
Delbaldo C
[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].
Therapie. 2007 Mar-Apr;62(2):87-90. Epub 2007 Jun 21.
- PubMed ID
- 17582306 [ View in PubMed]
- Abstract
Imatinib (Glivec) is a specific inhibitor of tyrosine kinase receptor, in particular of the proto-oncogene c-kit. Proto-oncogene c-kit is expressed or mutated in stromal digestive tumors (GIST). Pharmacokinetic (PK) analysis showed that imatinib displayed linear PK in patients with advanced GIST. Imatinib is extensively metabolized by the cytochrome P450 enzyme system. Alpha-1-acid glycoprotein (AAG), a protein involved in the acute phase of inflammation, is implicated in protein binding of imatinib and seems to play a key role in imatinib PK.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Imatinib High affinity nerve growth factor receptor Protein Humans UnknownAntagonistDetails